De-risking RNA therapeutics with high-resolution sequencing

In this on-demand webinar, Eclipsebio showcases how its eMERGE platform leverages nanopore sequencing to directly measure critical quality attributes—including base identity, poly(A) tail length, RNA integrity, and secondary structure within lipid nanoparticles. Learn how integrating sequencing-driven insights across development and manufacturing can reduce risk and strengthen confidence as RNA programs advance toward the clinic.